Haleon PLC Sponsored ADR $HLN Shares Bought by Ascent Group LLC

Key Points

• Ascent Group LLC has increased its holdings in Haleon PLC Sponsored ADR by 140.8%, owning a total of 133,093 shares valued at approximately $1.38 million at the end of the previous quarter.
• Haleon recently raised its semi-annual dividend to $0.0555 per share, reflecting a significant increase from its previous dividend and a yield of 190.0%.
• Analysts have mixed opinions on Haleon's stock, with Goldman Sachs upgrading it to a "buy" rating while Barclays downgraded it to "equal weight"; the consensus rating is currently "Moderate Buy" with a target price of $12.33.

Ascent Group LLC boosted its holdings in shares of Haleon PLC Sponsored ADR (NYSE:HLN - Free Report) by 140.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 133,093 shares of the company's stock after purchasing an additional 77,825 shares during the period. Ascent Group LLC's holdings in Haleon were worth $1,380,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Hilltop National Bank acquired a new stake in shares of Haleon during the 2nd quarter valued at $33,000. Paradiem LLC acquired a new stake in shares of Haleon during the second quarter worth $1,939,000. HB Wealth Management LLC lifted its holdings in shares of Haleon by 47.2% during the second quarter. HB Wealth Management LLC now owns 134,796 shares of the company's stock valued at $1,398,000 after purchasing an additional 43,202 shares during the last quarter. Janney Montgomery Scott LLC boosted its position in shares of Haleon by 1.4% in the 2nd quarter. Janney Montgomery Scott LLC now owns 901,775 shares of the company's stock valued at $9,351,000 after purchasing an additional 12,381 shares during the period. Finally, Hanson & Doremus Investment Management increased its stake in Haleon by 234.1% in the 2nd quarter. Hanson & Doremus Investment Management now owns 2,372 shares of the company's stock worth $25,000 after purchasing an additional 1,662 shares in the last quarter. Institutional investors and hedge funds own 6.67% of the company's stock.

Haleon Stock Up 0.6%

HLN stock opened at $8.94 on Monday. The company has a 50 day moving average of $9.50 and a two-hundred day moving average of $10.07. The company has a market cap of $39.81 billion, a price-to-earnings ratio of 22.91, a PEG ratio of 2.65 and a beta of 0.20. Haleon PLC Sponsored ADR has a 12-month low of $8.71 and a 12-month high of $11.42. The company has a quick ratio of 0.63, a current ratio of 0.87 and a debt-to-equity ratio of 0.48.

Haleon Increases Dividend

The company also recently announced a semi-annual dividend, which was paid on Thursday, September 18th. Shareholders of record on Friday, August 15th were paid a $0.0555 dividend. This represents a yield of 190.0%. This is an increase from Haleon's previous semi-annual dividend of $0.05. The ex-dividend date was Friday, August 15th. Haleon's dividend payout ratio is presently 28.21%.

Analyst Upgrades and Downgrades

A number of research firms have commented on HLN. The Goldman Sachs Group raised shares of Haleon from a "neutral" rating to a "buy" rating in a research note on Wednesday, September 10th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Haleon in a research note on Saturday, September 27th. Barclays downgraded shares of Haleon from an "overweight" rating to an "equal weight" rating in a research note on Tuesday, September 16th. Finally, Wall Street Zen cut Haleon from a "buy" rating to a "hold" rating in a research report on Saturday, July 12th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $12.33.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.